Violich Capital Management Inc. Sells 141 Shares of Thermo Fisher Scientific Inc. $TMO

Violich Capital Management Inc. trimmed its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,011 shares of the medical research company’s stock after selling 141 shares during the quarter. Violich Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $410,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Goldstein Advisors LLC boosted its position in Thermo Fisher Scientific by 13.7% during the second quarter. Goldstein Advisors LLC now owns 632 shares of the medical research company’s stock worth $256,000 after purchasing an additional 76 shares during the period. Novare Capital Management LLC boosted its position in shares of Thermo Fisher Scientific by 8.1% in the second quarter. Novare Capital Management LLC now owns 24,496 shares of the medical research company’s stock valued at $9,932,000 after acquiring an additional 1,834 shares during the period. Koshinski Asset Management Inc. boosted its position in shares of Thermo Fisher Scientific by 3.1% in the second quarter. Koshinski Asset Management Inc. now owns 3,236 shares of the medical research company’s stock valued at $1,312,000 after acquiring an additional 96 shares during the period. Citizens Business Bank boosted its position in shares of Thermo Fisher Scientific by 0.7% in the second quarter. Citizens Business Bank now owns 6,254 shares of the medical research company’s stock valued at $2,536,000 after acquiring an additional 42 shares during the period. Finally, Curbstone Financial Management Corp boosted its position in shares of Thermo Fisher Scientific by 3.8% in the second quarter. Curbstone Financial Management Corp now owns 1,366 shares of the medical research company’s stock valued at $554,000 after acquiring an additional 50 shares during the period. 89.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. UBS Group boosted their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a research report on Thursday, July 24th. Wells Fargo & Company cut their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a research report on Thursday, July 24th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, October 14th. Barclays upped their price objective on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an “overweight” rating in a research report on Thursday, October 2nd. Finally, HSBC reaffirmed a “hold” rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Fifteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $589.10.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $539.05 on Friday. The business has a 50 day moving average of $495.74 and a 200-day moving average of $449.13. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The company has a market capitalization of $203.55 billion, a P/E ratio of 31.18, a P/E/G ratio of 2.93 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the prior year, the firm posted $5.37 earnings per share. The firm’s revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the sale, the chief executive officer owned 115,174 shares of the company’s stock, valued at approximately $57,697,567.04. This represents a 7.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at $1,142,408.97. This represents a 14.24% decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock valued at $14,182,963 over the last quarter. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.